User:Mr. Ibrahem/Mitapivat
 | |
| Clinical data | |
|---|---|
| Trade names | Pyrukynd |
| Other names | AG-348, Mitapivat sulfate (USAN US) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Drug class | Pyruvate kinase activator[1] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C24H26N4O3S |
| Molar mass | 450.56 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia in those with pyruvate kinase deficiency.[1] It is approved in adults.[2] It is taken by mouth.[1]
Common side effects include trouble sleeping, back pain, nausea, and joint pain.[1][2] Safety in pregnancy is unclear.[1] It is a pyruvate kinase activator.[1]
Mitapivat was approved for medical use in the United States and Europe in 2022.[1][2] In the United States 4 weeks of treatment costs about 27,000 USD as of 2022.[3] It is not commercially available in the United Kingdom as of 2022.[4]
References[edit]
- ^ a b c d e f g h i j "Pyrukynd- mitapivat tablet, film coated Pyrukynd- mitapivat kit". DailyMed. 23 February 2022. Archived from the original on 3 March 2022. Retrieved 3 March 2022.
- ^ a b c d e "Pyrukynd EPAR". European Medicines Agency (EMA). 14 September 2022. Archived from the original on 6 December 2022. Retrieved 5 December 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Pyrukynd Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 11 December 2022.
- ^ "Mitapivat". SPS - Specialist Pharmacy Service. 3 November 2019. Archived from the original on 12 August 2022. Retrieved 11 December 2022.